I now have comprehensive content. Let me compile the complete, authoritative answer:
Type 2 Diabetes Mellitus (T2DM): Diagnosis & Treatment — Step by Step
PART 1 — PATHOPHYSIOLOGY IN BRIEF
T2DM is characterized by two core defects:
- Insulin resistance — peripheral tissues (muscle, liver, adipose) fail to respond normally to insulin
- Progressive β-cell dysfunction — the pancreas cannot compensate with sufficient insulin secretion
Unlike T1DM, autoimmune destruction is absent. The disease progresses silently for years, making screening critical.
PART 2 — WHO IS AT RISK? (Screen These Patients First)
| Risk Factor | Detail |
|---|
| Age ≥ 35–45 years | Screen all asymptomatic adults |
| Overweight/Obesity | BMI > 25 (>23 in Asian populations) |
| Family history | First-degree relative with T2DM |
| Physical inactivity | Sedentary lifestyle |
| Prediabetes | Prior IFG, IGT, or HbA1c 5.7–6.4% |
| Hypertension | BP ≥ 140/90 mmHg |
| Dyslipidemia | HDL < 35, TG > 250 mg/dL |
| History of GDM | Gestational diabetes |
| PCOS | Polycystic ovary syndrome |
| Ethnicity | African American, Hispanic, Asian, Native American |
The ADA recommends screening overweight/obese adults with any one risk factor above, and universal screening at age 35+ regardless of risk factors.
— Henry's Clinical Diagnosis and Management by Laboratory Methods
PART 3 — DIAGNOSTIC CRITERIA (ADA Standard)
Any one of the following confirms diabetes (confirmed on repeat testing in asymptomatic individuals):
| Test | Diagnostic Threshold |
|---|
| HbA1c | ≥ 6.5% (≥ 48 mmol/mol) |
| Fasting Plasma Glucose (FPG) | ≥ 126 mg/dL (≥ 7.0 mmol/L) — fasting = no caloric intake for ≥8 hrs |
| 2-hour Plasma Glucose (OGTT) | ≥ 200 mg/dL (≥ 11.1 mmol/L) using 75g oral glucose load |
| Random Plasma Glucose | ≥ 200 mg/dL + classic symptoms (polyuria, polydipsia, unexplained weight loss) |
"In a patient without classic symptoms, a single abnormal test result is not sufficient for diagnosis. A confirmatory test is required." — Tietz Textbook of Laboratory Medicine, 7th Ed
Prediabetes (High Risk — Not Yet Diabetes)
| Category | Value |
|---|
| Impaired Fasting Glucose (IFG) | FPG 100–125 mg/dL (5.6–6.9 mmol/L) |
| Impaired Glucose Tolerance (IGT) | 2-hr OGTT 140–199 mg/dL (7.8–11.0 mmol/L) |
| Intermediate HbA1c | 5.7–6.4% (39–46 mmol/mol) |
Prediabetes carries a 5-year cumulative diabetes incidence of 12–25% and also increases cardiovascular risk. — Tietz Textbook of Laboratory Medicine, 7th Ed
PART 4 — INITIAL WORKUP AT DIAGNOSIS
After confirming diabetes, perform the following baseline evaluations:
Glycemic:
- HbA1c (establishes baseline control)
- Fasting glucose
Renal & Cardiovascular:
- Urine albumin-to-creatinine ratio (microalbuminuria)
- Serum creatinine + eGFR
- Lipid panel (LDL, HDL, TG, total cholesterol)
- Blood pressure
Organ Screening:
- Dilated retinal exam (diabetic retinopathy)
- Neurologic exam / monofilament test (peripheral neuropathy)
- ECG if cardiovascular risk is high
- Thyroid function (TSH) — commonly coexists
PART 5 — TREATMENT: STEP-BY-STEP ALGORITHM
Treatment algorithm for T2DM — Goodman & Gilman's Pharmacological Basis of Therapeutics
STEP 1 — Lifestyle Modification (All Patients, Always)
Start at diagnosis and reinforce at every visit.
- Medical Nutrition Therapy: Reduce refined carbohydrates, saturated fat; increase fiber; caloric deficit if obese
- Physical Activity: Minimum 150 min/week of moderate aerobic exercise (e.g., brisk walking)
- Weight Loss: Even 5–10% body weight reduction significantly improves insulin sensitivity
- Smoking cessation, alcohol moderation
- Diabetes education — self-monitoring of blood glucose (SMBG), foot care, hypoglycemia recognition
STEP 2 — First-Line Pharmacotherapy: Metformin
Start metformin at the time of diagnosis, alongside lifestyle changes.
- Mechanism: Decreases hepatic gluconeogenesis; increases insulin sensitivity via AMPK activation
- Dose: Start 500 mg once or twice daily with meals; titrate to 1000 mg twice daily
- Target: HbA1c ≤ 7% (individualized — may be stricter [6.5%] for young/newly diagnosed, or looser [8%] for elderly/frail)
- Advantages: Weight neutral to modest weight loss, no hypoglycemia, cardiovascular benefit (UKPDS), low cost
- Contraindications: eGFR < 30 mL/min/1.73m², active liver disease, alcohol excess, contrast dye procedures
"Metformin is generally accepted as the first-line treatment of type 2 diabetes and is the most commonly used oral agent." — Goodman & Gilman's, 14th Ed
Reassess HbA1c in 2–3 months.
STEP 3 — Second Agent (If HbA1c Target Not Met)
If HbA1c remains above goal on metformin monotherapy, add a second agent based on comorbidities:
| Priority Condition | Preferred Add-On |
|---|
| ASCVD (established CV disease) | GLP-1 receptor agonist (liraglutide, semaglutide) OR SGLT-2 inhibitor (empagliflozin, dapagliflozin) |
| Heart Failure | SGLT-2 inhibitor (empagliflozin, dapagliflozin) |
| Diabetic Nephropathy (CKD) | SGLT-2 inhibitor first; GLP-1 RA as alternative |
| Obesity / Weight loss desired | GLP-1 receptor agonist (semaglutide, liraglutide) |
| Hypoglycemia risk | DPP-4 inhibitor (sitagliptin, saxagliptin) — weight neutral, no hypoglycemia |
| Cost is major concern | Sulfonylurea (glimepiride, glipizide) — effective, cheap; risk of hypoglycemia + weight gain |
STEP 4 — Triple Therapy or Insulin
If dual therapy is insufficient:
- Add a third oral/injectable agent, OR
- Initiate basal insulin (long-acting: glargine, detemir, degludec) — typically at bedtime, combined with oral agents
- Start: 10 units/day (or 0.1–0.2 units/kg/day); titrate by 2 units every 3 days until fasting glucose 80–130 mg/dL
- As β-cell function declines, transition to basal-bolus insulin (basal + prandial doses at meals)
"Progressive insulin deficiency in type 2 diabetes often makes it increasingly difficult to achieve the glycemic goal solely with oral agents; thus, insulin is necessary in a substantial proportion." — Goodman & Gilman's
GLYCEMIC TARGETS SUMMARY
| Measure | General Target | Notes |
|---|
| HbA1c | < 7% | < 6.5% in young/newly dx; < 8% in elderly/frail |
| Fasting glucose | 80–130 mg/dL | |
| 2-hr post-prandial | < 180 mg/dL | |
| Blood pressure | < 130/80 mmHg | |
| LDL cholesterol | < 100 mg/dL (< 70 if ASCVD) | Statin therapy for most patients |
PART 6 — MONITORING & FOLLOW-UP
| Test | Frequency |
|---|
| HbA1c | Every 3 months until at goal, then every 6 months |
| Fasting glucose / SMBG | As indicated by medication regimen |
| Urine albumin (microalbuminuria) | Annually |
| eGFR / serum creatinine | Annually |
| Lipid panel | Annually |
| Retinal exam | Annually (or every 1–2 years if stable) |
| Foot exam (monofilament) | Annually or at every visit |
| Blood pressure | Every visit |
| Dental exam | Annually |
PART 7 — COMPLICATION PREVENTION
| Complication | Prevention Strategy |
|---|
| Retinopathy | Tight glycemic + BP control; annual retinal screening |
| Nephropathy | SGLT-2 inhibitors; ACE inhibitors/ARBs for microalbuminuria |
| Neuropathy | Glycemic control; foot care; gabapentin/duloxetine for pain |
| Cardiovascular disease | Statin, antihypertensive, aspirin (if high CV risk), GLP-1 RA or SGLT-2i |
| Foot ulcers | Regular inspection, appropriate footwear, monofilament testing |
QUICK SUMMARY FLOWCHART
Screening (risk factors or age ≥35)
↓
Diagnostic Testing (FPG, HbA1c, OGTT)
↓
Confirm T2DM Diagnosis
↓
Baseline Workup (HbA1c, lipids, eGFR, urine albumin, retinal exam, neuro exam)
↓
STEP 1: Lifestyle + Metformin → Reassess HbA1c in 3 months
↓ (if not at goal)
STEP 2: Metformin + Second Agent (chosen by comorbidities)
↓ (if not at goal)
STEP 3: Triple Therapy or Add Basal Insulin
↓ (progressive disease)
STEP 4: Basal-Bolus Insulin ± Oral Agents
Sources: Tietz Textbook of Laboratory Medicine, 7th Ed | Goodman & Gilman's Pharmacological Basis of Therapeutics, 14th Ed | Goldman-Cecil Medicine | Henry's Clinical Diagnosis and Management | ADA Standards of Medical Care in Diabetes